Protocol Ledger

NCT03749447 · Phase III · TERMINATED

An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)

Interventional Phase III clinical trial protocol NCT03749447 sponsored by Biogen in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-03-08 Enrollment: 270 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03749447
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)270 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03749447
Protocol FieldVerified Registry Value
NCT IdentifierNCT03749447
Consolidated Lead SponsorBiogen
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment270 participants (ACTUAL)
Registered Start Date2019-03-08
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Biogen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI